Infiltrative Myocardial T-Cell Lymphoma Authors: Alexander Podgorski, Daniel Tardo, Callum Cherrett, Orly Lavee, Jason C Kovacic Published: 2024 ABSTRACT AbstractWe report a unique case involving cardiac manifestation of T-cell lymphoma and associated risk management of ventricular arrhythmia and sudden cardiac death. A 39-year-old woman presented with a syndrome consistent with fever in a returned traveler, ultimately diagnosed with stage IV peripheral T-cell lymphoma involving the myocardium with ventricular tachycardia. Management of risk of sudden cardiac death was complicated by hematological management with an antibody-drug conjugate chemotherapy regimen and later autologous stem cell transplant. There was no significant evidence base to consult for management of the present case. Management proceeded on careful multidisciplinary team discussion, risk assessment extrapolated from cardiac sarcoidosis, and consideration of a vulnerable and previously health young patient.Key Words: awareness, cancer, cardiac risk, imaging, positron emission tomography, secondary prevention, treatment, ventricular tachycardia History of Presentation A 39-year-old woman presented multiple times to the emergency department with fevers, dry cough, abdominal pain, and migratory rash over several weeks after returning from international travel to various locations in Southeast Asia and Central America. Take-Home Messages •This case highlights T-cell lymphoma as a rare cause of infiltrative cardiomyopathy and myocarditis. This case highlights T-cell lymphoma as a rare cause of infiltrative cardiomyopathy and myocarditis. •Improvements in therapy of hematological malignancies with cardiac manifestations are unmasking new management issues, in this case, management of VA risk. Improvements in therapy of hematological malignancies with cardiac manifestations are unmasking new management issues, in this case, management of VA risk. Her relevant exposure history included freshwater swimming and sustaining insect bites in the absence of malaria prophylaxis. Clinical examination but for the rash was unremarkable, and emergency department investigations across serial chest x-rays revealed mildly increased interstitial markings. Computed tomography (CT) of the abdomen revealed no acute pathology. The patient declined admission on multiple occasions and was initially managed by the infectious diseases team as an outpatient, as a fever in returned traveler syndrome presumptively as atypical pneumonia, with oral antibiotic coverage. On her third presentation, 21 days after first presenting to the emergency department, vital signs were: heart rate 103 beats/min, blood pressure 119/82 mm Hg, temperature 36.3 °C, and respiratory rate 18 breaths/min. The presenting symptom was a dry cough with hemoptysis, and visual disturbance including floaters and headache, suggestive of ocular migraine. Additionally, the patient had developed chest pain with tachycardia, with an electrocardiogram showing sinus tachycardia without repolarization abnormalities or ischemic changes. Initial high-sensitivity troponin I was elevated at 900 ng/mL rising to 1,750 ng/mL at 4 hours and the patient was admitted under the cardiology service and placed on cardiac telemetry. Past Medical History The patient’s past medical history included Dengue fever, confirmed by positive serology. She reported no regular medications and was anaphylactic to penicillin. The patient was a nonsmoker, was a nondrinker, was active and independent, and had no significant family history. Differential Diagnosis and Investigations CT pulmonary angiogram before admission excluded pulmonary embolus. Blood cultures, thick and thin films, and atypical infective serologies were negative, with convalescent testing also sent. An acute inflammatory response demonstrated mild neutrophilia with an elevated C-reactive protein of 103 mg/L. Transthoracic echocardiography revealed a left ventricular ejection fraction of 70%, with no wall motion abnormalities, valvulopathies, or pericardial pathology. Invasive coronary angiogram revealed normal coronary arteries with no evidence of spasm or spontaneous coronary artery dissection. Cardiac telemetry showed a significant burden of ventricular ectopy and captured runs of nonsustained ventricular tachycardia (NSVT) (Figure 1). The patient described only occasional palpitations, and otherwise had no syncope. Cardiac Telemetry Nonsustained Ventricular Tachycardia Cardiac telemetry showing captured run of 10 beats of nonsustained ventricular tachycardia (red box). Subsequent cardiac magnetic resonance (CMR) (Figure 2) showed late gadolinium enhancement in the basal to mid inferior and basal lateral walls of the left ventricle (LV), with active edema on T2-weighted imaging, concerning for an infiltrative or myocarditic process. Cardiac positron emission tomography (PET)-CT imaging (Figure 3) showed corresponding fluorodeoxyglucose (FDG) tracer uptake in the basal myocardium without perfusion or wall motion defects corresponding to the findings on CMR. Additionally, tracer uptake was also noted in multiple lymph nodes within the thoracic inlet (Figure 3), and subcutaneous and intramuscular focal abnormalities of uncertain etiology in the lower limbs (Figure 4). Of note, significant lymphadenopathy by size criteria was not evident on the preadmission CT pulmonary angiography. Cardiac Magnetic Resonance Imaging (Initial) Cardiac magnetic resonance imaging on day 1 of admission showing late gadolinium enhancement of basal to mid inferior left ventricular wall (left image, red arrows) and basal posterolateral and inferior walls (right image, red arrows). Positron Emission Tomography (Initial) Positron emission tomography-computed tomography on day 3 of admission showing uptake of fluorodeoxyglucose in multiple lymph nodes within the thoracic inlet (large, superior red box) and myocardium (small, inferior red box). Positron Emission Tomography Lower Limbs (Initial) Positron emission tomography-computed tomography on day 3 of admission displaying multiple subcutaneous and intramuscular fluorodeoxyglucose-avid foci. Broad systemic differential diagnoses were considered, including cardiac sarcoidosis, vasculitis, autoimmune disorders, and neoplastic disease, with multidisciplinary involvement with further subspecialist investigations arranged. Notably, there was mild anemia with hemoglobin of 105 g/L; however, there were no other significant cytopenias or elevated cell counts. A core biopsy was pursued of one of the FDG-avid lower limb subcutaneous nodules, revealing nonspecific findings of lymphocytoclastic vasculitis with insufficient tissue for further diagnosis. A second core biopsy of a nodule in the right gluteal region was again nondiagnostic. Peripheral blood flow cytometry revealed a mildly elevated CD4+ T-cell population suggestive of clonality, with normal B-cell and immunoglobulin populations. The differentials for this included T-cell lymphoma or an autoimmune process. Given significant anxiety surrounding procedures, the patient initially refused a bone marrow biopsy. During this period of investigation, intermittent NSVT continued despite stable LV function. Serial measurement of troponin I revealed fluctuating levels, decreasing to a nadir of 13 ng/mL that climbed to 3,560 ng/mL with recurrence of chest pain. Despite no clear diagnosis prednisolone was commenced at 1 mg/kg once daily on day 25 of admission in consultation with the Immunology service. Repeat transthoracic echocardiogram was unremarkable. Troponin I was consistently elevated, and on day 28 of admission repeat CMR (Figure 5) showed progressive myocardial inflammation with LV wall effacement and repeat cardiac PET-CT (Figure 6) indicated progression of a multiorgan progress most in-keeping with systemic vasculitis or lymphoma. Cardiac Magnetic Resonance Imaging (Prechemotherapy) Cardiac magnetic resonance imaging on day 27 of admission showing progression since initial study of late gadolinium enhancement in basal to mid inferior left ventricular wall (left image, red arrows) and basal posterolateral and inferior walls (right image, red arrows). Positron Emission Tomography (Prechemotherapy) Positron emission tomography-computed tomography on day 34 of admission showing progression since initial study of thoracic inlet lymphadenopathy (red box) and myocardium. With cardiac imaging progression, the patient agreed to a bone marrow biopsy, with results highly suggestive of a monoclonal T-cell population. Restaining of peripheral core biopsy samples for T- and B-cell markers were consistent with T-cell infiltration. These revised results together with flow cytometry and bone marrow samples resulted in a multidisciplinary team meeting that led to a diagnosis of stage IV peripheral T-cell lymphoma not otherwise specified, a result taking 4 weeks from the time of admission. Management Following diagnosis, emergent treatment with a first cycle of chemotherapy comprising an antibody-drug conjugate regimen of brentuximab vedotin, cyclophosphamide, doxorubicin, and high-dose prednisolone was initiated in the coronary care unit on cardiac telemetry. This proceeded on the basis that the myocardial process was a primary T-cell lymphoma, rather than a secondary paraneoplastic process. Endomyocardial biopsy was considered to answer this question, but the location of the infiltration in the free LV wall was deemed too high risk to pursue. During the first cycle of treatment, there was no cardiac decompensation associated with chemotherapy responsiveness of the infiltrative lymphomatous tissue. However, there remained a high degree of uncertainty regarding the risk of ventricular arrhythmias (VAs) associated with chemotherapy-induced tumor cell death. Following consultation with the electrophysiology service, it was felt that her sudden cardiac death risk was such that she warranted an implantable cardioverter-defibrillator upon discharge from the hospital. However, there was concern about infection risk with a transvenous device given her immunosuppressed state and the likely need for central venous lines during treatment regimes. A subcutaneous cardioverter-defibrillator was considered, although it still posed an infection risk in the context of her chemotherapy-induced neutropenia. There was also uncertainty whether her sudden cardiac death (SCD) risk would remain elevated following treatment, and so, ultimately, a wearable external defibrillator was offered to the patient and fitted before discharge. The defibrillator was programmed to discharge at 150 J, with the ventricular tachycardia zone set from 180 beats/min (with a response time of 60 seconds) and a ventricular fibrillation zone from 200 beats/min (with a response time of 25 seconds). The total days of admission to hospital was 45, with subsequent chemotherapy cycles administered as an outpatient with close hematology and cardiology follow-up. Following the third of 6 cycles of chemotherapy, a restaging PET-CT demonstrated complete metabolic response of the tumor despite initial high-grade disease. Interrogation of the wearable external defibrillator revealed no shocks delivered and no NSVT. At 12 weeks, the device was returned by the patient. A follow-up transthoracic echocardiogram remained unchanged. The patient completed 6 cycles of chemotherapy and was planned for an autologous stem-cell transplant at 3 months postcompletion of chemotherapy. Outcome and Follow-Up Before autologous stem cell transplant, PET-CT showed no residual disease (Figure 7), and CMR displayed residual LV wall thinning but no new inflammation (Figure 8). The patient underwent autologous stem cell harvest followed by myeloablative therapy. In the days following bone marrow transplant, the patient developed symptoms of a profound cytokine release syndrome and required admission to the intensive care unit in the setting of elevated troponins as high as 20,000 ng/mL. Cardiac function stabilized, however, the patient experienced progressive multiorgan failure and required hemodialysis, in addition to marked derangement of liver function studies. Despite negative FDG-avid foci on serial PET-CT and no peripheral blood flow cytometry evidence of T-cell clonality, the patient was ultimately diagnosed with recurrence of the initial lymphoma based on repeat bone marrow biopsy, which was performed on the basis of persistent transfusion-dependent cytopenias, suspicious for recurrent or refractory disease. At 8 weeks postautologous stem cell transplant, in the setting of recurrence of malignancy, polymicrobial sepsis, and multiorgan failure, the patient opted for comfort measures together with family rather than pursuing further treatment. Positron Emission Tomography (Postchemotherapy) Positron emission tomography-computed tomography showing complete pathological response of T-cell lymphoma following completion of 3 of 6 cycles of chemotherapy, completion of 6 of 6 cycles of chemotherapy, and before autologous stem cell transplantation. Cardiac Magnetic Resonance Imaging (Postchemotherapy) Cardiac resonance imaging performed postcompletion of 6 of 6 cycles of chemotherapy, showing residual left ventricular wall thinning without new foci of infiltration or inflammation. Discussion No guideline-level evidence exists surrounding risk management for SCD in the context of cardio-oncology—a significant but underdeveloped space. In managing this case, it was thought that the most analogous guideline evidence was that of VA-SCD risk management in sarcoidosis,1 although this link was considered to be tenuous. Initially at issue was the uncertainty regarding the etiology of the myocardial infiltration without myocardial tissue diagnosis, with clinical suspicion for infiltrative lymphoma or paraneoplastic syndrome, or inflammatory states such as a vasculitis or sarcoidosis. Although a direct biopsy of the cardiac lesion was considered, this required it to be performed in the free wall of the left ventricle, deemed to be of high risk in this unstable patient. Rather, we persisted with trying to reach a diagnosis by analyzing peripheral and bone marrow biopsy samples together, with final management decisions made on the assumption that the cardiac lesion was a deposit related to primary T-cell lymphoma that would be responsive to chemotherapy. This approach is analogous to the diagnostic algorithm for cardiac sarcoidosis, whereby the etiology of a cardiac lesion can be inferred to be sarcoidosis if there is adequate pathologic evidence from other sites and in the correct context. Risk of SCD from VA in this patient was thought to be multifactorial. The cardiac lesion had a clear causative link with NSVT but the risk of further VA postchemotherapy was unknown. It was uncertain if tumor death from chemotherapy would result in resolution of VA, or, promote electrical instability in the myocardium because of increased tissue edema and thus increase the risk of SCD. In either case, it remained unclear what level of tumor response to therapy was required before risk of SCD would begin to decline, although it was speculated that this may have been proportional to the number of cycles of chemotherapy. Further, even given complete pathological response to therapy, residual myocardial damage could still leave the patient with a clinically significant risk of SCD and need for an indwelling automated defibrillator, any implantation of which would likely need to be following recovery from future autologous stem cell transplant. Conclusions T-cell lymphomas present heterogeneously, and may have rare but clinically significant cardiac complications, in this case, VA. The wide array of clinical features and difficulties achieving a tissue diagnosis presented a complex clinical challenge to arrive at a definitive management plan for this patient. Our decision to proceed with a wearable external defibrillator facilitated earlier outpatient management, and ultimately provided time for further VA risk assessment. The psychological impact of the protracted initial hospital admission, diagnostic uncertainty, multiple procedures, risk of SCD, and superimposed high-dose prednisolone was profound. At several stages of admission, psychiatry consultation was required because the patient wished to discharge against medical advice. Although her mental state improved dramatically following discharge for outpatient chemotherapy, we continued to be mindful of the impact of such a dramatic patient journey for this previously healthy 39-year-old. Visual Summary. Timeline of the Case MDT = multi-disciplinary team; RWMA = regional wall motion abnormality. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Acknowledgments The authors acknowledge this brave patient who fought until the end, and her wonderfully supportive family. Given the nature of this case and that the patient was deceased, the St. Vincent’s Hospital Sydney human research ethics committee granted a waiver of the requirement for formal review. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Reference